ANIP FY 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$883M+43.8% YoY

Gross Profit

$451M51.0% margin

Operating Income

$81M9.2% margin

Net Income

$78M8.9% margin

EPS (Diluted)

$3.32

Cash Flow

Operating Cash Flow

$185M

Free Cash Flow

$171M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$900M

Stockholders' Equity

$541M

Cash & Equivalents

$286M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$883M	$614M	+43.8%
Gross Profit	$451M	$364M	+23.7%
Operating Income	$81M	$584,000	+13809.2%
Net Income	$78M	-$19M	+522.9%